|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future|
|Hyojin Kim, Jin-Haeng Chung|
|JPTM. 2019;53(4):199-206. Published online 2019 May 2 DOI: https://doi.org/10.4132/jptm.2019.04.24|
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy
Are endobronchial ultrasound-guided transbronchial needle aspiration samples adequate for PD-L1 testing in non-small cell lung cancer?
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer
Combined modality therapy for non-small cell lung cancer, past, present, and future
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
Concurrent chemoradiation for stage III non small cell lung cancer: Present results and future prospects
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
|This metadata service is kindly provided by CrossRef from May 29, 2014. J Pathol Transl Med has participated in CrossRef Text and Data Mining service since January 16, 2015.|